The impressive prevalence of over-expression of uPAR and uPA in malignant human cancers, together with the fact that the uPA/uPAR system is not essential for fertility or survival under physiological conditions, makes targeting of this system by recombinant inhibitors very promising. The gene discussed is PLAU; the disease is cancer.